Intraoperative Somatostatin Receptor Detection After Peptide Receptor Radionuclide Therapy with 177Lu- and 90Y-DOTATOC (Tandem PRRNT) in a Patient with a Metastatic Neuroendocrine Tumor
Abstract
Aim The aim of this chapter is to present the results of the first intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy (PRRNT) with (90)Y- and (177)Lu-DOTATOC using a handheld gamma probe and comparison with the findings of preoperative (68)Ga-DOTATOC PET/CT in a patient with a metastatic neuroendocrine tumor (NET) of the ileum.Materials and methods A 56-year-old female patient, treated twice by PRRNT, was admitted for the third cycle and subsequent surgery. Before operation, the following studies were performed for restaging after the second cycle of PRRNT: (99m)Tc-MAG3 + TER, (99m)Tc-DTPA + GFR, abdominal ultrasonography, MRI of the abdomen, (68)Ga-DOTATOC PET/CT as well as (18)F-fluoride PET/CT. Serum tumor markers were measured before and after PRRNT. Tandem PRRNT was performed using 3000 MBq (90)Y-DOTATOC and 6000 MBq (177)Lu-DOTATOC. Whole-body scintigrams were obtained at 23 and 43 h. Five days after PRRNT, the patient was operated using a handheld gamma probe. Immunohistochemistry and histopathology of the resected tissue were performed.Results Tandem PRRNT was very well tolerated by the patient. Before PRRNT, (68)Ga-DOTATOC PET/CT revealed the primary tumor in the ileocoecal region as well as bilobular liver metastases and a right iliac bone lesion (osteoblastic on (18)F-fluoride PET/CT). Compared with the previous findings, there was good therapy response (partial remission of the tumor lesions). No nephrotoxicity was observed. Serum chromogranin A (836 μg/l, n < 100) and serotonin (852 μg/l, n < 200) were strongly elevated. Posttherapy scans showed intense uptake in metastases and the primary tumor. Intraoperative gamma probe detected-in addition to the known lesions-bilateral ovarian metastases not visualized by (68)Ga-DOTATOC PET/CT. Bilateral adnexectomy, right hemicolectomy, excision of hepatic metastases in S3, and partial resection of peritoneum were performed. Histopathology confirmed metastases in both ovaries.Conclusions Gamma probe-guided surgery after (177)Lu PRRNT is feasible and appears to be more sensitive than (68)Ga-DOTATOC PET/CT. This technique might aid the surgeon in achieving more complete tumor resection through intraoperative detection of very small lesions (<5 mm) directly after PRRNT.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An increasing number of clinical studies suggest that the combination of 90Y and 177Lu could be better than either radionuclide alone for PRRT in NETs, with an improved overall survival.
“An increasing number of clinical studies suggest that the combination of 90Y and 177Lu could be better than either radionuclide alone for PRRT in NETs, with an improved overall survival (55, 56).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [55]
Cites
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. S. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,742 · see citing works
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L. R., van Eijck, C. H. J., van Essen, M., Kooij, P. P. M., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,454 · see citing works
Sutton, R., Doran, H. E., Williams, E. M. I., et al. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100469 · Cited by 96 · see citing works
Neoadjuvant peptide receptor radionuclide therapy for aninoperable neuroendocrine pancreatic tumor
Kaemmerer, D., Prasad, V., Daffner, W., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5867 · Cited by 84 · see citing works
Self-citationIntraoperative gamma probe detection of neuroendocrine tumors.
Adams, S., Baum, R. P., Hertel, A., et al. (1998) · PubMed · Cited by 81 · see citing works
Self-citationMolecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system
Wiedenmann, B., John, M., Ahnert‐Hilger, G., et al. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050261 · Cited by 64 · see citing works
Cytoreductive Surgery in Patients with Advanced-Stage Carcinoid Tumors
Güleç, S. A., Mountcastle, T. S., FREY, D. J., Cundiff, J. D., Mathews, E., Anthony, L. B., O’Leary, J. P., & Boudreaux, J. P. (2002) · The American Surgeon · doi:10.1177/000313480206800803 · Cited by 59 · see citing works
Radioguided Surgery in Neuroendocrine Tumors Using Ga-68-Labeled Somatostatin Analogs
Kaemmerer, D., Prasad, V., Daffner, W., et al. (2012) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3182291de8 · Cited by 40 · see citing works
Self-citationIntraoperative use of gamma-detecting probes to localize neuroendocrine tumors.
Adams, S., & Baum, R. P. (2000) · PubMed · Cited by 38 · see citing works
Self-citationRadio‐guided surgery in neuroendocrine tumors
Güleç, S. A., & Baum, R. P. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20868 · Cited by 29 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works
Self-citation
- Authors
- Todorović-Tirnanić, M., Kaemmerer, D., Prasad, V., Hommann, M., & Baum, R. P.
- Affiliations
- University of Belgrade (RS)
- Zentralklinik Bad Berka (DE)
- Corresponding author
- Baum, Richard P.
- Venue
- Recent Results in Cancer Research
- Publisher
- Springer Berlin Heidelberg
- Published
- 2012-08-24
- Volume
- 194
- Pages
- 487-496
- ISSN
- 0080-0015 (ISSN-L)
- OpenAlex
- W246736197
- Cited by
- 10
- References
- 10
- Citations by year
- 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2017: 2 · 2015: 3
- FWCI
- 4.19
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- Locations
- Recent results in cancer research/Recent Results in Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- peptide receptor radionuclide therapy, 177Lu-DOTATOC, 90Y-DOTATOC, hand-held gamma probe, intraoperative imaging, neuroendocrine tumors, ileal neuroendocrine tumor, liver metastasis, ovarian metastasis, 68Ga-DOTATOC PET/CT
- MeSH terms
- Female, Humans, Intraoperative Period, Liver Neoplasms, Lutetium, Middle Aged, Radioisotopes, Tomography, X-Ray Computed, Octreotide, Receptors, Somatostatin, Neuroendocrine Tumors, Radiopharmaceuticals, Positron-Emission Tomography, Multimodal Imaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review